創傷ケア用生物製剤市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、エンドユーザー別、地域別、競合別セグメント、2019-2029年

創傷ケア用生物製剤の世界市場規模は2023年に19億1,000万米ドルとなり、予測期間では2029年までCAGR 6.12%で着実な成長が見込まれます。

創傷ケア用生物製剤とは、急性および慢性創傷の管理および治療に使用される治療用製品のカテゴリーを指します。ドレッシング材や局所軟膏のような従来の創傷治療製品とは異なり、創傷ケア用生物製剤は生物または生物学的ソースに由来し、創傷治癒、組織再生、修復を促進する生物活性物質を含んでいます。これらの生物学的製剤は、創傷閉鎖を促進し、瘢痕形成を最小限に抑え、創傷治癒障害に伴う合併症のリスクを軽減するために、身体の自然治癒メカニズムを利用します。成長因子は、細胞増殖、血管新生（新生血管の形成）、細胞外マトリックスの合成など、創傷治癒に関与する細胞プロセスを制御するタンパク質です。

血小板由来成長因子（PDGF）、トランスフォーミング成長因子β（TGF-B）、血管内皮成長因子（VEGF）などの成長因子を含む創傷ケア用生物製剤は組織修復を刺激し、肉芽組織の形成を促進し、創傷閉鎖と再生を促進します。創傷ケア用生物製剤に基づく細胞外マトリックス（ECM）は、構造タンパク質、糖タンパク質、プロテオグリカンからなる三次元の足場を提供し、組織の自然な細胞外環境を模倣します。ECMは細胞の接着、移動、分化を促進し、慢性創傷や非治癒性創傷の組織再生とリモデリングを促進します。細胞療法では、間葉系幹細胞（MSC）、線維芽細胞、ケラチノサイトなどの生きた細胞を用いて創傷治癒と組織再生を促進します。これらの細胞は、炎症反応を調節し、血管新生を刺激し、コラーゲンの沈着を促進し、創傷閉鎖と上皮化を促進するパラクリン因子、サイトカイン、成長因子を放出します。

バイオテクノロジーと再生医療における技術の進歩は、革新的な創傷ケア用生物製剤製品の開発につながった。これらの製品は、成長因子、サイトカイン、幹細胞、組織工学的構築物などの生物学的材料を活用し、創傷治癒、組織再生、修復を促進します。有効性、安全性、患者の転帰を改善する高度な創傷治療ソリューションへの需要が高まっています。創傷ケア用生物製剤製品は、自然治癒プロセスを刺激し、創傷閉鎖を促進し、合併症のリスクを軽減する生物学的に活性な成分を提供することで、この需要に対応しています。患者やヘルスケアプロバイダーは、患者の不快感や回復時間を最小限に抑えながら、治癒結果を最適化する低侵襲・非侵襲の創傷治療法をますます好むようになってきています。創傷ケア用生物製剤は、外科的デブリードマンや皮膚移植といった従来の創傷治療法に代わる侵襲性の低い治療法を提供し、複雑な創傷を管理するための魅力的な選択肢となっています。

市場促進要因

バイオテクノロジーと再生医療の進歩

高度な創傷治療ソリューションに対する需要の高まり

低侵襲・非侵襲治療への嗜好の高まり

主な市場課題

コスト制約

市場競合

主な市場動向

戦略的提携とパートナーシップ

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の創傷ケア用生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（生物学的皮膚代替物、外用剤）
  • 傷の種類別（潰瘍、外科的および外傷性の傷、火傷）
  • エンドユーザー別（病院、急性期外科病院、火傷センター、創傷クリニック）
  • 地域別
  • 企業別（2023）
• 市場マップ

第6章 北米の創傷ケア用生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 傷の種類別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の創傷ケア用生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 傷の種類別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の創傷ケア用生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 傷の種類別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の創傷ケア用生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 傷の種類別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの創傷ケア用生物製剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 傷の種類別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併および買収（該当する場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Smith & Nephew Plc
• Molnlycke Health Care AB
• Integra LifeSciences Corporation
• Wright Medical Group N.V.
• MiMedx Group, Inc.
• Vericel Corporation
• Osiris Therapeutics, Inc.
• Organogenesis Holdings Inc.
• Solsys Medical, LLC
• Lavior Pharma Inc.
• Marine Polymer Technologies, Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Wound Care Biologics Market was valued at USD 1.91 billion in 2023 and will see a steady growth in the forecast period at a CAGR of 6.12% through 2029. Wound care biologics refers to a category of therapeutic products used in the management and treatment of acute and chronic wounds. Unlike traditional wound care products such as dressings and topical ointments, wound care biologics are derived from living organisms or biological sources and contain bioactive substances that promote wound healing, tissue regeneration, and repair. These biologics harness the body's natural healing mechanisms to accelerate wound closure, minimize scarring, and reduce the risk of complications associated with impaired wound healing. Growth factors are proteins that regulate cellular processes involved in wound healing, including cell proliferation, angiogenesis (formation of new blood vessels), and extracellular matrix synthesis.

Wound care biologics containing growth factors such as platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-B), and vascular endothelial growth factor (VEGF) stimulate tissue repair and promote the formation of granulation tissue, enhancing wound closure and regeneration. Extracellular Matrices (ECMs) based wound care biologics provide a three-dimensional scaffold composed of structural proteins, glycoproteins, and proteoglycans that mimic the natural extracellular environment of tissues. ECMs facilitate cell adhesion, migration, and differentiation, promoting tissue regeneration and remodeling in chronic and non-healing wounds. Cellular therapies involve the use of living cells, such as mesenchymal stem cells (MSCs), fibroblasts, or keratinocytes, to promote wound healing and tissue regeneration. These cells release paracrine factors, cytokines, and growth factors that modulate inflammatory responses, stimulate angiogenesis, and enhance collagen deposition, facilitating wound closure and epithelialization.

Technological advancements in biotechnology and regenerative medicine have led to the development of innovative wound care biologics products. These products leverage biological materials, such as growth factors, cytokines, stem cells, and tissue-engineered constructs, to promote wound healing, tissue regeneration, and repair. There is a growing demand for advanced wound care solutions that offer improved efficacy, safety, and patient outcomes. Wound care biologics products address this demand by providing biologically active components that stimulate the natural healing process, accelerate wound closure, and reduce the risk of complications. Patients and healthcare providers increasingly prefer minimally invasive and non-invasive wound care treatments that optimize healing outcomes while minimizing patient discomfort and recovery time. Wound care biologics offer a less invasive alternative to traditional wound care modalities, such as surgical debridement and skin grafting, making them attractive options for managing complex wounds.

Key Market Drivers

Advancements in Biotechnology and Regenerative Medicine

Biotechnology has enabled the production and utilization of growth factors, such as platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-B), and vascular endothelial growth factor (VEGF), which play crucial roles in stimulating cellular proliferation, angiogenesis, and tissue remodeling during wound healing. Cytokines and chemokines are signaling molecules that regulate inflammatory responses, immune cell recruitment, and tissue repair processes. Biotechnology has facilitated the isolation, purification, and recombinant production of cytokines and chemokines for therapeutic use in wound care biologics. Stem cells, including mesenchymal stem cells (MSCs) and adipose-derived stem cells (ASCs), have emerged as promising tools for promoting wound healing and tissue regeneration.

Biotechnology enables the isolation, expansion, and manipulation of stem cells to enhance their regenerative potential and therapeutic efficacy in wound care applications. Extracellular matrix (ECM) scaffolds provide a three-dimensional framework that mimics the natural extracellular environment and supports cell adhesion, migration, and differentiation. Biotechnology allows for the development of ECM scaffolds derived from natural sources (e.g., decellularized tissues) or synthesized materials (e.g., hydrogels) for use as wound dressings or tissue-engineered constructs. Gene therapy holds promise for enhancing wound healing and tissue regeneration by delivering therapeutic genes encoding growth factors, cytokines, or other bioactive molecules directly to the wound site. Biotechnology enables the design and delivery of gene therapy vectors, such as viral vectors or nanoparticles, to target specific cell populations and promote desired biological responses.

Tissue engineering and 3D bioprinting technologies enable the fabrication of complex tissue constructs with precise spatial organization and functionality. Biotechnology-driven advances in biomaterials, cell culture techniques, and bioprinting processes allow for the creation of custom-designed skin substitutes, vascular grafts, and organoids for wound repair and regeneration. Biotechnology has facilitated the development of smart wound dressings and drug delivery systems that incorporate bioactive agents, nanoparticles, or microspheres to modulate wound microenvironment and promote healing. These advanced dressings and delivery systems enable controlled release of therapeutic molecules, antimicrobial agents, or growth factors to accelerate wound closure and prevent infections. This factor will help in the development of the Global Wound Care Biologics Market.

Growing Demand for Advanced Wound Care Solutions

As the population ages and the prevalence of chronic diseases like diabetes and vascular conditions rises, healthcare providers encounter more complex wound cases. These wounds often require advanced treatment modalities beyond traditional dressings and antibiotics. Wound care biologics offer innovative solutions that can address the challenges presented by chronic and non-healing wounds. Wound care biology harnesses the body's natural healing mechanisms to promote tissue regeneration and wound closure. They contain bioactive components such as growth factors, cytokines, and extracellular matrices that stimulate cell proliferation, angiogenesis, and collagen synthesis. These properties make biologics particularly effective in promoting healing in challenging wound environments. Advanced wound care solutions, including biologics, have been shown to reduce healing time and healthcare costs compared to traditional wound care methods. By accelerating the healing process and minimizing the risk of complications such as infections and amputations, biologics can lead to shorter hospital stays, fewer outpatient visits, and lower overall healthcare expenditures.

Patients increasingly seek treatments that offer faster healing, improved outcomes, and enhanced quality of life. Advanced wound care solutions, including biologics, align with the principles of patient-centered care by providing personalized and targeted therapies that address individual wound characteristics and patient needs. This focus on patient outcomes drives the demand for innovative wound care products and technologies. The growing body of clinical evidence supporting the efficacy and safety of wound care biologics has contributed to their widespread adoption in clinical practice. Clinical practice guidelines and recommendations from professional organizations endorse the use of biologics in certain wound care scenarios, further driving their demand among healthcare providers and institutions. Advances in biotechnology, tissue engineering, and regenerative medicine have spurred the development of increasingly sophisticated wound care biologics. These innovations enable the design of biologics with enhanced therapeutic properties, improved biocompatibility, and longer shelf life, making them more appealing to healthcare providers and patients alike. This factor will pace up the demand of the Global Wound Care Biologics Market.

Rising Preference for Minimally Invasive and Non-Invasive Treatments

Minimally invasive and non-invasive treatments typically involve less pain, discomfort, and trauma compared to traditional surgical interventions. Patients prefer treatments that minimize physical discomfort and promote faster recovery, making them more inclined towards biologic-based wound care solutions. Minimally invasive and non-invasive wound care biologics often promote faster healing and recovery times compared to surgical procedures. These treatments leverage the body's natural healing processes to stimulate tissue regeneration and wound closure, leading to quicker resolution of wounds and improved patient outcomes. Biologics-based wound care products, including growth factors, skin substitutes, and extracellular matrices, offer targeted and precise mechanisms of action that minimize the risk of adverse events and promote optimal wound healing. Many minimally invasive and non-invasive wound care procedures can be performed in outpatient settings, reducing the need for hospitalization and associated healthcare costs. Patients prefer treatments that allow them to return to their daily activities quickly and resume normal functioning without prolonged hospital stays or post-operative care requirements.

Minimally invasive and non-invasive wound care treatments often result in better cosmesis, and aesthetics compared to surgical interventions. Biologics-based wound care products facilitate the formation of organized and functional tissue, minimizing scarring, pigmentation changes, and other cosmetic concerns associated with surgical procedures. Patient preference and compliance play a crucial role in treatment outcomes and patient satisfaction. Patients are more likely to adhere to treatment regimens that are minimally invasive, comfortable, and convenient, leading to better treatment adherence and overall outcomes in wound care management. Advances in biotechnology and regenerative medicine have led to the development of increasingly sophisticated minimally invasive and non-invasive wound care biologics. These products offer targeted and precise mechanisms of action, allowing for customized treatment approaches tailored to individual patient needs and wound characteristics. This factor will accelerate the demand of the Global Wound Care Biologics Market.

Key Market Challenges

Cost Constraints

Wound care biology often involves higher initial acquisition costs compared to traditional wound care products such as dressings and topical treatments. The production, development, and purification processes involved in manufacturing biologics can be complex and expensive, leading to higher prices for these products. Reimbursement policies and coverage for wound care biologics vary across healthcare systems and insurance plans. In some cases, reimbursement may be limited or unavailable for certain biologics-based treatments, making them less accessible to patients or healthcare providers. Lack of adequate reimbursement can deter healthcare providers from prescribing biologics or limit patient access to these advanced treatment options. Healthcare providers and institutions are under pressure to optimize resource utilization and control healthcare costs. While wound care biologics may offer clinical benefits such as faster healing and reduced complications, their cost-effectiveness compared to traditional treatments is often scrutinized.

Demonstrating the cost-effectiveness of biologics-based interventions through comparative effectiveness studies and economic evaluations is essential to justify their adoption and reimbursement in clinical practice. Affordability is a critical consideration for patients who may bear out-of-pocket costs for wound care biologics, especially if these treatments are not fully covered by insurance or healthcare plans. High co-payments, deductibles, or lack of insurance coverage can present financial barriers that limit patient access to biologics-based therapies, particularly for individuals with limited financial resources or underinsured populations. Healthcare institutions, including hospitals, clinics, and long-term care facilities, operate within finite budgets and resource constraints. Allocating financial resources for expensive wound care biologics may compete with other healthcare priorities and essential services, making it challenging to justify the upfront investment in these products despite their potential long-term benefits.

Market Competition

The wound care biologics market is characterized by a growing number of competing products from various manufacturers. These products may offer similar therapeutic benefits or target overlapping patient populations, leading to intense competition for market share and differentiation based on product efficacy, safety, and cost-effectiveness. Price competition is prevalent in the wound care biologics market, with manufacturers under pressure to offer competitive pricing while maintaining profitability. Price discounts, rebates, and contracting negotiations with healthcare providers and payers can erode profit margins and impact revenue growth, especially in markets with high price sensitivity or limited reimbursement.

Market consolidation through mergers, acquisitions, and strategic partnerships can reshape the competitive landscape in the wound care biologics market. Larger companies with greater financial resources may acquire smaller competitors or innovative startups to expand their product portfolios, increase market share, and gain a competitive advantage in key market segments. Intellectual property rights and patent protection play a crucial role in maintaining a competitive edge in the wound care biologics market. Companies invest significant resources in research and development to innovate new products and technologies, and protecting intellectual property rights through patents and trademarks is essential to safeguarding market exclusivity and preventing infringement by competitors.

Key Market Trends

Strategic Collaborations and Partnerships

Collaborations enable companies to leverage complementary expertise, resources, and capabilities to accelerate innovation and product development in the wound care biologics space. Partnering with research institutions, academic centers, and contract research organizations provides access to scientific knowledge, preclinical models, and clinical expertise necessary for advancing biologic-based therapies. Collaborative partnerships allow companies to share risks, costs, and investments associated with research, development, and commercialization of wound care biologics products. Pooling financial resources, intellectual property, and infrastructure minimizes individual companies' exposure to market uncertainties and enhances cost efficiency in product development and commercialization efforts. Strategic collaborations enable companies to expand their product portfolios and pipeline of wound care biologics offerings through licensing agreements, acquisitions, and joint ventures.

Partnering with other companies or acquiring innovative startups with complementary technologies or product candidates enhances companies' competitive positions and market presence in the wound care biologics market. Collaborative partnerships facilitate access to global markets and distribution networks, allowing companies to penetrate new geographical regions and target patient populations effectively. Partnering with distributors, healthcare providers, and market access organizations enhances companies' reach, visibility, and market penetration for wound care biologics products. Collaborative partnerships foster patient-centric innovation and translational research in the wound care biologics field by engaging patients, caregivers, and advocacy organizations in product design, clinical trials, and post-market surveillance activities. Patient-centered collaborations enhance the relevance, acceptability, and effectiveness of wound care biologics therapies, ultimately improving patient outcomes and quality of life.

Segmental Insights

Product Insights

The Biologic Skin Substitutes segment is projected to experience rapid growth in the Global Wound Care Biologics Market during the forecast period. Biologic skin substitutes have demonstrated effectiveness in promoting wound healing, especially in complex and chronic wounds. These substitutes provide a biologically active matrix that supports cell proliferation, angiogenesis, and tissue regeneration, facilitating the natural healing process. Advances in tissue engineering technologies have led to the development of biologic skin substitutes with enhanced regenerative properties. These substitutes mimic the structure and function of native skin, promoting integration with the wound bed and facilitating the formation of new tissue. Chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, pose significant challenges in wound management.

Biologic skin substitutes offer a promising solution for the treatment of chronic wounds by providing a conducive environment for cell migration, proliferation, and differentiation, leading to accelerated wound closure. Biologic skin substitutes have been shown to reduce healing time and improve wound closure rates compared to traditional wound care modalities. The active components present in these substitutes, such as growth factors, cytokines, and extracellular matrix proteins, promote tissue regeneration and remodeling, resulting in faster wound healing outcomes. Biologic skin substitutes help minimize scarring and contractures by promoting the formation of organized and functional tissue during the wound healing process. By providing structural support and modulating inflammatory responses, these substitutes contribute to improved cosmetic outcomes and functional restoration in patients with traumatic injuries or surgical wounds.

Wound Type Insights

The Burns segment is projected to experience significant dominance in the Global Wound Care Biologics Market during the forecast period. Burns are a common type of injury globally, resulting from various causes such as fire accidents, chemical exposure, electrical mishaps, and thermal injuries. The prevalence of burns remains significant across different demographics, driving the demand for effective wound care solutions, including biologics. Burns, especially severe burns, often require specialized medical attention and advanced wound care interventions to promote healing, prevent infections, and minimize scarring. Biologics-based wound care products offer unique advantages in managing complex burn injuries, including promoting tissue regeneration, reducing inflammation, and enhancing wound closure.

The development of innovative biologics-based wound care technologies has revolutionized the management of burn injuries. Products such as skin substitutes, growth factors, and stem cell therapies have demonstrated promising results in promoting faster wound healing, minimizing complications, and improving patient outcomes in burn care. Effective wound management in burn injuries is critical for reducing complications such as infections, hypertrophic scarring, contractures, and loss of function. Biologics-based wound care products, with their ability to stimulate tissue regeneration, modulate inflammation, and enhance wound closure, offer promising solutions for mitigating these complications and improving long-term outcomes in burn patients. The field of regenerative medicine, which focuses on harnessing the body's natural healing mechanisms to restore tissue structure and function, has gained significant traction in burn care. Biologics-based wound care products play a pivotal role in regenerative medicine approaches by promoting tissue repair, angiogenesis, and remodeling in burn injuries.

Regional Insights

North America emerged as the dominant region in the Global Wound Care Biologics Market in 2023. North America is home to advanced healthcare infrastructure and cutting-edge technology. The region has been at the forefront of developing and adopting innovative wound care biologics products and treatment modalities, contributing to its dominant position in the market. North America has a significant population affected by chronic wounds, such as diabetic foot ulcers, pressure ulcers, and venous leg ulcers. Factors such as aging populations, increasing rates of obesity, and higher incidences of diabetes contribute to the prevalence of chronic wounds in the region, driving the demand for advanced wound care solutions, including biologics.

North America has robust regulatory agencies, such as the Food and Drug Administration (FDA) in the United States and Health Canada, which set stringent standards for the approval and commercialization of wound care biologics products. Compliance with regulatory requirements enhances consumer confidence and facilitates market penetration for manufacturers. The region's substantial healthcare expenditure, coupled with favorable reimbursement policies for advanced wound care treatments, encourages investment in biologics-based wound care products. Patients in North America have relatively better access to these innovative treatments compared to other regions.

Key Market Players

Smith & Nephew Plc

Molnlycke Health Care AB

Integra LifeSciences Corporation

Wright Medical Group N.V.

MiMedx Group, Inc.

Vericel Corporation

Osiris Therapeutics, Inc.

Organogenesis Holdings Inc.

Solsys Medical, LLC

Lavior Pharma Inc.

Marine Polymer Technologies, Inc.

Report Scope:

In this report, the Global Wound Care Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Wound Care Biologics Market, By Product:

Biologic Skin Substitutes Topical Agents

Wound Care Biologics Market, By Wound Type:

Ulcers Surgical and Traumatic Wounds Burns

Wound Care Biologics Market, By End User:

Hospitals ASCs Burn Centers Wound Clinics

Wound Care Biologics Market, By Region:

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Asia-Pacific

China

Japan

India

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Wound Care Biologics Market.

Available Customizations:

Global Wound Care Biologics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Wound Care Biologics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Biologic Skin Substitutes, Topical Agents)
  • 5.2.2. By Wound Type (Ulcers, Surgical and Traumatic Wounds, Burns)
  • 5.2.3. By End User (Hospitals, ASCs, Burn Centers, and Wound Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map

6. North America Wound Care Biologics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Wound Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Wound Care Biologics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Wound Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Wound Care Biologics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Wound Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Wound Care Biologics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Wound Type
      • 6.3.3.2.3. By End User

7. Europe Wound Care Biologics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Wound Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Wound Care Biologics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Wound Type
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Wound Care Biologics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Wound Type
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Wound Care Biologics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Wound Type
      • 7.3.3.2.3. By End User
  • 7.3.4. France Wound Care Biologics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Wound Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Wound Care Biologics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Wound Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Wound Care Biologics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Wound Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Wound Care Biologics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Wound Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Wound Care Biologics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Wound Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Wound Care Biologics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Wound Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Wound Care Biologics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Wound Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Wound Care Biologics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Wound Type
      • 8.3.5.2.3. By End User

9. South America Wound Care Biologics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Wound Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Wound Care Biologics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Wound Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Wound Care Biologics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Wound Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Wound Care Biologics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Wound Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Wound Care Biologics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Wound Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Wound Care Biologics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Wound Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Wound Care Biologics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Wound Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Wound Care Biologics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Wound Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Smith & Nephew Plc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Molnlycke Health Care AB
• 14.3. Integra LifeSciences Corporation
• 14.4. Wright Medical Group N.V.
• 14.5. MiMedx Group, Inc.
• 14.6. Vericel Corporation
• 14.7. Osiris Therapeutics, Inc.
• 14.8. Organogenesis Holdings Inc.
• 14.9. Solsys Medical, LLC
• 14.10. Lavior Pharma Inc.
• 14.11. Marine Polymer Technologies, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer